Liquid Biopsy in Lung Cancer

NCT03479099 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2019-08-28

No results posted yet for this study

Summary

The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.

Conditions

  • Lung Cancer (Diagnosis)
  • Circulating Tumor Cell

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2019-03-11
Completion
2019-03-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03479099 on ClinicalTrials.gov